# US 6,951,650 B1 · Antigenic class of avian reoviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,951,650 B1
- Document ID: US6951650B1
- Status: Granted
- Kind: B1
- Application number: 09/493,484
- Filed: 2000-01-28
- Granted: 2005-10-04
- Earliest claimed: 1999-01-29
- Assignees: Akzo Nobel N.V.
- Inventors: Adriaan Anthonius Wilhelmus Maria van Loon
- Web page: https://patentgrep.com/patent/US6951650B1

## CPC

- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 39/12: Viral antigens
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/5252: {inactivated (killed)}
- C12N 2720/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a new antigenic class of avian reoviruses which are involved in enteric disease conditions in poultry. Moreover, the invention provides a vaccine for use in the protection of poultry against such disease conditions derived from the new type of avian reoviruses.

## Claims

### Claim 1

A vaccine comprising an isolated avian reovirus belonging to an antigenic class of avian ERS reoviruses wherein the avian reovirus is able to induce antiserum in an animal, which causes a reduction of the plaques formed by avian reovirus ERS(isolate 1), deposited at the ECACC under accession no. 99011475, of at least 75% in a plaque reduction assay and wherein the avian reovirus positively reacts with polyclonal avian reovirus antiserum raised against strain 1133, but not with monoclonal antibodies identified by accessions nos. 99011472, 99011473 and 99011474, samples of which are deposited at the ECAC, and a pharmaceutical acceptable carrier or diluent.

### Claim 2 (depends on 1)

The vaccine according to claim 1, which is in a live attenuated form.

### Claim 3 (depends on 1)

The vaccine according to claim 1, which is in an inactivated form.

### Claim 4 (depends on 1)

The vaccine according to claim 1, which further comprises an adjuvant.

### Claim 5 (depends on 1)

The vaccine according to claim 1, which further comprises one or more vaccine components of other pathogens infections to poultry.

### Claim 6

A vaccine comprising an avian reovirus which is avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, and a pharmaceutically acceptable carrier or diluent.

### Claim 7 (depends on 5)

The vaccine of claim 5 wherein the one or more vaccine components comprises at least one vaccine component selected from the group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, fowl adenovirus, EDS virus and turkey rhinotracheitis virus.

### Claim 8 (depends on 5)

The vaccine of claim 5 wherein the one or more vaccine components are either one of a live attenuated form or an inactivated form.

### Claim 9 (depends on 1)

The vaccine of claim 1 wherein the avian reovirus is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 80% in a plaque reduction assay.

### Claim 10 (depends on 1)

The vaccine of claim 1 wherein the avian reovirus is able to induce antiserum in an animal, which anitserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 90% in a plaque reduction assay.